Skip to content

mRNA Expression in Lymphocytes of Glaucoma Patients

Messenger Ribonucleic Acid Expression in Lymphocytes of Glaucoma Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00327509
Enrollment
60
Registered
2006-05-18
Start date
2004-01-31
Completion date
2007-12-31
Last updated
2009-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Healthy Subjects

Keywords

mRNA, glaucoma

Brief summary

The aim of the study is to compare messenger ribonucleic acid (mRNA) expression of various genes in lymphocytes between glaucoma patients and sex and age-matched healthy subjects. A secondary objective is to analyze the impact of different forms of glaucoma or of a vasospastic propensity on the findings.

Detailed description

Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The glaucoma patients will be divided into four groups: (1) high tension glaucoma, (2) normal tension glaucoma, (3) pseudoexfoliation glaucoma, and (4) juvenile glaucoma. Healthy subjects are separated into two age groups. Vasospastic propensity will be assessed with a questionnaire: patients and subjects answering yes to the questions: do you have always cold hands, even during summer time? and do other people tell you that you have cold hands? will be classified as vasospastic, and as normals if they deny a history of cold hands. Blood will be drawn from an arm vein, lymphocytes will be isolated and mRNA of following genes will be assessed in these lymphocytes: Nuclear proteins: NF-kappa B, XPGC, P53, XIAP; Multi-drug resistance proteins: ABC 1, ABC 8, MDR 3; Adhesion protein: ICAM 1; Blood brain barrier breakdown protein: P2Y; Energy metabolism proteins: Adrenodoxin, Adrenodoxin-reductase, Cytochrome p450, Cytochrome-reductase, Alcohol-dehydrogenase; Tissue remodeling proteins: MMP 9, MMP 8, MMP 14, TIMP 1, TIMP 2, TIMP 3, TIMP 4.

Interventions

None listed

Sponsors

University of Bonn
CollaboratorOTHER
University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

Glaucoma patients * diagnosis of chronic glaucoma with typical glaucomatous disc and visual field damage * a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment HTG) * a present or past diurnal tension curve with an average intraocular pressure below 21 mmHg without treatment (NTG) * a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment and signs of pseudoexfoliation in the anterior segment (PEX) * a juvenile-onset open-angle glaucoma with a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment (Juvenile Glaucoma) Healthy subjects * no history of ocular disease * no history of systemic disease * no history of alcohol/drug abuse * normal blood pressure (100-140 / 60-90 mmHg) * best corrected visual acuity above 20/25 in both eyes * no pathological findings upon a slit-lamp examination and indirect fundoscopy * IOP \< 20 mmHg in both eyes

Exclusion criteria

* Ametropia \> 3 dpt * Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy * Pigmentary dispersion * any abnormality which in the physician's view would prevent reliable applanation tonometry * History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis * History of ocular trauma or intraocular surgery within the past 6 months * History of infection or inflammation within the past 3 months * History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment * Need for any concomitant medications that may interfere with the evaluation of ocular blood flow * significant history and/or active alcohol or drug abuse

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026